Investigational drug · Phase 2
BEAM-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sickle Cell Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BEAM-101"
First trial start
2022
Aug 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BEAM-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sickle Cell Disease
Approved drugs for the same conditions: Sickle cell disease · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BEAM-101" as an intervention, largest first.
Beam Therapeutics Inc.Industry
NCT07373639 · 50 participants (planned) · Start Dec 15, 2025 · Primary completion Feb 12, 2043
Drug: Long-Term Follow-up Study of patients who received BEAM-101 · For: Hemoglobinopathy; Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Jacksonville, Florida · 17 sites in all
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell DiseaseActive, not recruiting
Beam Therapeutics Inc.Industry
NCT05456880 · 15 participants (planned) · Start Aug 30, 2022 · Primary completion Feb 2028
Drug: BEAM-101 · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Jacksonville, Florida · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Sickle Cell Disease
- FT-4202EtavopivatPhase 36 trials
Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia
- Exa-celPhase 31 trial
Vertex Pharmaceuticals · Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- TebapivatAG-946Phase 22 trials
Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease
- AnumigilimabPhase 21 trial
CSL Behring · Sickle Cell Disease
- ITU512Phase 21 trial
Novartis · Sickle Cell Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.